Progressive Supranuclear Palsy (PSP) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Progressive Supranuclear Palsy (PSP) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.” report has been added to ResearchAndMarkets.com’s offering.
The report covers 8 drugs currently in different phases of development.
The report provides PSP treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.
Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Key Topics Covered
1.1. Research Methodology
1.2. Research Scope
2. Disease Overview
3. Executive Summary
4. Market Dynamics
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by PhaseDrug Name Generic Name Synonyms Company Collaborator Route of administration Target Mechanism of Action Technology Molecule type CAS Number Weight Chemical Formula IUPAC name ATC code
5.3. By Molecule Type
5.4. Analysis by Region
6. Company Profiling
6.1. AbbVie Inc.
6.2. Biogen International
6.3. Cortice Biosciences
6.4. AlzProtect SAS
6.5. Asceneuron SA
6.6. SELLAS Life Sciences
6.7. TauRx Pharmaceuticals
6.8. Prana Biotechnology Limited
For more information about this report visit https://www.researchandmarkets.com/research/g5xbth/progressive?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180605005764/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs,Clinical Trials
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/05/2018 04:27 AM/DISC: 06/05/2018 04:27 AM